drugset / Trial / NCT04049383
CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL
Phase 1
Terminated
5 enrolled
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase 1 study will evaluate the safety and efficacy of a CAR-T cell therapy directed against two B cell antigens (CD19 CD20) and produced under good manufacturing practice (GMP) conditions using the closed system CliniMACS Prodigy device in B ALL.
Timeline
- Start
- 2020-10-16
- Primary completion
- 2025-06-01
- Completion
- 2025-09-01
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-20/19-T cells | Cell therapy | 500000 cells/kg | Intravenous |
| Subject | CAR-20/19-T cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CAR-20/19-T cells | Cell therapy | 2.5e+06 cells/kg | Intravenous |